Categories: News

Day One to Present at the 21st Annual Needham Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13 at 3:45 p.m. ET.

A live audio webcast of the discussion will be available by visiting the Events & Presentations section of the Company’s website. An archived replay of the webcast will be available for 30 days following the live presentation.

About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for patients of all ages with life-threatening diseases. Day One was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. The Company’s name was inspired by the “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.

Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, tovorafenib (DAY101), is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor and the pipeline also includes pimasertib, an investigational, oral, highly-selective small molecule inhibitor of mitogen‐activated protein kinases 1 and 2 (MEK-1/-2). Day One is based in South San Francisco. For more information, please visit www.dayonebio.com or find the company on LinkedIn or Twitter.

Contacts:

Media:
1AB
Dan Budwick
dan@1abmedia.com

Investors:
LifeSci Advisors
Hans Vitzthum
hans@lifesciadvisors.com

Staff

Recent Posts

Dr. Shahrooz Yazdani Launches $6M Dental Practice Seminar Series to Help Owners Break Free from Burnout

Seminar offers step-by-step blueprint to grow your clinic, build passive income, and regain personal timeOTTAWA,…

1 hour ago

New Aura and UNC-Chapel Hill Study Finds One in Three Kids Have Accessed GenAI Apps

BOSTON, Feb. 2, 2026 /PRNewswire/ -- Aura, a leading AI-powered online safety platform for families,…

1 hour ago

‘Breathable’ Launches to Bring Hope and Humanity Back to Mental Health Care

New online network makes it simple, affordable and stigma-free to connect with licensed therapistsDETROIT, Feb.…

1 hour ago

Digital X-ray Market worth $7.50 billion by 2031 | MarketsandMarkets™

DELRAY BEACH, Fla., Feb. 2, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Digital X-ray Market…

1 hour ago

mPATH® Health Earns DiMe Seal for Quality and Trust in Digital Health

WINSTON-SALEM, N.C., Feb. 2, 2026 /PRNewswire/ -- mPATH® Health, a digital health company focused on improving…

1 hour ago

TeachTown Partners with Tulsa Public Schools to Maximize Student Outcomes

WOBURN, Mass., Feb. 2, 2026 /PRNewswire/ -- TeachTown, a leading provider of special education curriculum for…

1 hour ago